Chronic kidney disease: appropriateness of therapeutic management and associated factors in the AVENIR study.
暂无分享,去创建一个
Michèle Kessler | Luc Frimat | Serge Briançon | S. Briançon | L. Frimat | N. Thilly | M. Kessler | S. Boini | Nathalie Thilly | Stéphanie Boini
[1] A. Kshirsagar,et al. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] Madhumathi Rao,et al. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. , 2005, Kidney international.
[3] A. Nissenson,et al. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. , 2001, Journal of the American Society of Nephrology : JASN.
[4] John Simes,et al. Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease , 2004, Circulation.
[5] F. Port,et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] H. Feldman,et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[8] S. Briançon,et al. Nephrology referral and appropriateness of therapeutic drug care in chronic kidney disease. , 2006, Journal of nephrology.
[9] Charles E. McCulloch,et al. CHRONIC KIDNEY DISEASE AND THE RISKS OF DEATH, CARDIOVASCULAR EVENTS, AND HOSPITALIZATION , 2004 .
[10] C. Zoccali,et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. , 2006, Kidney international.
[11] B. Stengel,et al. Evaluation and Determinants of Underprescription of Erythropoiesis Stimulating Agents in Pre-Dialysis Patients with Anaemia , 2008, Nephron Clinical Practice.
[12] N. Unwin,et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .
[13] C. Leopold,et al. Time of Erythema Onset after Application of Methyl Nicotinate Ointments as Response Parameter: Influence of Penetration Kinetics and Enhancing Agents , 2006, Skin Pharmacology and Physiology.
[14] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[15] G J Kuperman,et al. Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. , 2001, American journal of hypertension.
[16] C. Maxwell,et al. Measurement, Correlates, and Health Outcomes of Medication Adherence Among Seniors , 2004, The Annals of pharmacotherapy.
[17] A. Kausz,et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. , 1999, Journal of the American Society of Nephrology : JASN.
[18] Michèle Kessler,et al. Impact of nephrology referral on early and midterm outcomes in ESRD: EPidémiologie de l'Insuffisance REnale chronique terminale en Lorraine (EPIREL): results of a 2-year, prospective, community-based study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] A. Levin,et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] Jerry Avorn,et al. The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. , 2003, Kidney international.
[21] A. Kausz,et al. Management of patients with chronic renal insufficiency in the Northeastern United States. , 2001, Journal of the American Society of Nephrology : JASN.
[22] F. Locatelli,et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] Keith C. Norris,et al. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] C. Maingourd,et al. Démographie des néphrologues en France en 2002. , 2003 .
[25] K. Sakhaee,et al. The clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] A. Kausz,et al. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. , 1999, Journal of the American Society of Nephrology : JASN.
[27] Bruce Kupelnick,et al. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease , 2004 .
[28] R. Wolfe,et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[29] Early referral of Type 2 diabetic patients: are we ready for the assault? , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.